tiprankstipranks
MacroGenics expands license agreement with Synaffix
The Fly

MacroGenics expands license agreement with Synaffix

MacroGenics has expanded its license agreement with Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates – ADCs -. The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2B, plus tiered low to high single-digit royalties on potential net sales of any resulting products. MacroGenics currently has the option to pursue up to seven ADC programs under the expanded deal, which includes three programs from the original collaboration. Under the original licensing agreement, MacroGenics gained access to Synaffix’s clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability. These may be combined with MacroGenics’ proprietary antibody and bispecific DART platform technologies to generate next-generation ADCs.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MGNX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles